^
    Back
    Association details:
    Biomarker:IKZF1 deletion + CDKN2A deletion
    Cancer:Acute Myelogenous Leukemia
    Drug:Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASH 2020
    Title:

    Prognostic Significance of Genetic Alterations in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD Plus Dasatinib or Hyper-CVAD Plus Ponatinib

    Published date:
    11/04/2020
    Excerpt:
    IKZF1plus(rev) group showed worse prognosis on EFS and OS than non-IKZF1plus(rev) group...In this study, unlike with dasatinib-based therapy, we demonstrated that IKZF1-driven high-risk group was associated with worse EFS and OS than IKZF1-driven low-risk in the context of Hyper-CVAD plus ponatinib.
    Secondary therapy:
    CVAD
    DOI:
    https://doi.org/10.1182/blood-2020-136676